Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 180, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.addr.2021.114068
Keywords
Lung cancer; RBP; HuR; siRNA; CRISPR; Cas-9; Nanomedicine; Drug delivery
Categories
Funding
- National Cancer Institute (NCI) of the National Institutes of Health (NIH) [R01 CA167516, R01 CA233201, R01 CA 254192]
- National Institute of General Medical Sciences of the National Institutes of Health [P20 GM103639]
- Department of Veterans Affairs [101BX003420A1]
- National Cancer Institute Cancer Center Support Grant [P30CA225520]
- Department of Defense (DOD) through the Lung Cancer Research Program (LCRP) [W81XWH-19-1-0647]
- Oklahoma Center for Advanced Science and Technology (OCAST) [HR18-088]
- Presbyterian Health Foundation Seed Grant
- Presbyterian Health Foundation Bridge Grant
- Oklahoma Tobacco Settlement Endowment Trust (TSET)
- Jim and Christy Everest Endowed Chair in Cancer Developmental Therapeutics
Ask authors/readers for more resources
Lung cancer is often diagnosed at an advanced stage with limited treatment options. RNA binding proteins, particularly Human antigen R (HuR), have been identified as key players in tumorigenesis, including lung cancer. This review explores the role of HuR in lung cancer progression and highlights various approaches, such as small molecule inhibitors, siRNAs, and shRNAs, for inhibiting HuR expression and function. These approaches have shown promising results in reducing tumor growth, invasion, migration, angiogenesis, and metastasis. Nanomedicine-based HuR targeting approaches using siRNA and shRNA delivery hold immense potential for enhancing cancer therapies in lung cancer patients.
Lung cancer (LC) is often diagnosed at an advanced stage and conventional treatments for disease man-agement have limitations associated with them. Novel therapeutic targets are thus avidly sought for the effective management of LC. RNA binding proteins (RBPs) have been convincingly established as key play -ers in tumorigenesis, and their dysregulation is linked to multiple cancers, including LC. In this context, we review the role of Human antigen R (HuR), an RBP that is overexpressed in LC, and further associated with various aspects of LC tumor growth and response to therapy. Herein, we describe the role of HuR in LC progression and outline the evidences supporting various pharmacologic and biologic approaches for inhibiting HuR expression and function. These approaches, including use of small molecule inhibitors, siRNAs and shRNAs, have demonstrated favorable results in reducing tumor cell growth, invasion and migration, angiogenesis and metastasis. Hence, HuR has significant potential as a key therapeutic target in LC. Use of siRNA-based approaches, however, have certain limitations that prevent their maximal exploitation as cancer therapies. To address this, in the conclusion of this review, we provide a list of nanomedicine-based HuR targeting approaches currently being employed for siRNA and shRNA delivery, and provide a rationale for the immense potential therapeutic benefits offered by nanocarrier-based HuR targeting and its promise for treating patients with LC.(c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available